Cisplatin-CBV with Autologous Bone Marrow Transplantation for Relapsed Hodgkin's Disease
作者:
SpinoloJorge A.,
JagannathSundar,
VelásquezWilliam,
SpitzerGary,
CabanillasFernando,
HagemeisterFredrick,
HorwitzLeonard J.,
DickeKarel A.,
期刊:
Leukemia&Lymphoma
(Taylor Available online 1993)
卷期:
Volume 9,
issue 1-2
页码: 71-77
ISSN:1042-8194
年代: 1993
DOI:10.3109/10428199309148506
出版商: Taylor&Francis
关键词: Cisplatinum/CBV;autologous bone marrow transplant;relapsed Hodgkin's disease
数据来源: Taylor
摘要:
The use of high-dose cyclophosphamide, carmustine, and etoposide (CBV) with autologous bone marrow transplantation (ABMT) results in long-term disease-free survival of about 30% in patients with relapsed Hodgkin's disease. Laboratory and clinical data show that cisplatin is synergistic with etoposide and carmustine, with non-overlapping extramedullary toxicity. Twenty-one patients with relapsed Hodgkin's disease that had progressed after both MOPP-like and ABVD-like regimens were treated with CBV plus cisplatin (90 mg/m2) and ABMT. The CR rate was 55%; the three-year disease-free and overall survival were 29% and 38% respectively; these results are comparable to prior experience with CBV. Performance status was strongly correlated with achievement of CR, survival, and time to treatment failure. Nephrotoxicity was seen in 3 patients, and ototoxicity in 1 patient. Although cisplatin could be added to CBV with minimal additional toxicity, the results obtained in this small patient population were not better than those of the earlier regimen. A larger trial in patients not previously exposed to cisplatin may better define the role of its addition to CBV.
点击下载:
PDF (550KB)
返 回